ArticleWound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
Integrating Transcriptomics, Network Pharmacology, Molecular Docking and Experimental Validation to Explore the Pharmacological Mechanisms of Chinese Medicinal Honey in Treating Diabetic Wounds.
Article in Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Chinese medicinal honey (CMH) is traditionally used for wounds, but its mechanisms in diabetic wounds are unclear. This study aimed to investigate the active components of CMH and the molecular mechanisms underlying its promotion of wound healing in individuals with diabetes to provide a preliminary experimental basis for its clinical application. The main components of CMH were analysed using ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS). An integrated strategy combining network pharmacology, transcriptomics, molecular docking and animal experiments was applied. A db/db diabetic mouse model was used to evaluate CMH in diabetic wound healing. Histopathology, immunohistochemistry, qRT-PCR and western blotting were performed to assess anti-inflammatory, antioxidant and pro-angiogenic effects. Fifty-two major CMH components, mainly flavonoids and phenolic acids, were identified. Network pharmacology and transcriptomics showed that CMH targets epidermal growth factor receptor (EGFR), interleukin (IL)-1β, matrix metallopeptidase 9 (MMP9) and prostaglandin-endoperoxide synthase 2 (PTGS2), with significant enrichment in the IL-17 signalling pathway. Molecular docking validated a strong binding affinity between CMH components and key targets, including IL-17A and NF-κB. In vivo findings suggest that CMH markedly accelerates wound healing in diabetic mice, reduces inflammation and oxidative stress, promotes collagen deposition and angiogenesis and suppresses the activity of the IL-17A/NF-κB pathway. This study provides a preliminary experimental basis of CMH. CMH supports diabetic wound healing through a multi-component, multi-target mechanism, primarily by inhibiting the IL-17A/NF-κB signalling pathway, thereby attenuating inflammation and oxidative stress and promoting angiogenesis and tissue repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.